Profile data is unavailable for this security.
About the company
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
- Revenue in GBP (TTM)33.33bn
- Net income in GBP4.31bn
- Incorporated1999
- Employees94.07k
- LocationGlaxoSmithKline PLCG S K House, 980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB SA | 4.68bn | 793.83m | 16.01bn | 8.41k | 20.36 | 2.39 | 14.69 | 3.42 | 4.77 | 4.79 | 28.02 | 40.63 | 0.4203 | 1.59 | 4.99 | 656,082.80 | 7.16 | 6.92 | 8.83 | 8.80 | 75.19 | 73.56 | 17.04 | 15.80 | 0.8582 | 17.86 | 0.2135 | 32.06 | 8.83 | 6.65 | -7.34 | 22.63 | 19.04 | -4.17 |
| Eurofins Scientific SE | 5.42bn | 905.01m | 18.40bn | 49.07k | 21.27 | 5.30 | 14.23 | 3.40 | 5.31 | 4.11 | 31.80 | 21.32 | 0.7628 | 30.45 | 5.62 | 123,994.50 | 13.17 | 6.28 | 16.35 | 8.02 | 30.17 | 21.25 | 17.27 | 10.13 | 1.28 | 14.40 | 0.3925 | 14.76 | 19.20 | 22.77 | 116.43 | 38.20 | 16.02 | 36.22 |
| Lonza Group AG | 3.23bn | 418.17m | 44.25bn | 14.41k | 106.09 | 7.47 | 54.78 | 13.68 | 6.88 | 9.52 | 53.25 | 97.83 | 0.2732 | -- | -- | 240,386.90 | 3.55 | 5.12 | 4.32 | 6.35 | 41.95 | 38.95 | 13.00 | 13.11 | -- | 26.49 | 0.3319 | 33.19 | 7.15 | 3.46 | 12.83 | 21.39 | 29.81 | 5.31 |
| GlaxoSmithKline plc | 33.33bn | 4.31bn | 76.73bn | 94.07k | 17.87 | 4.97 | 10.90 | 2.30 | 0.8536 | 0.8536 | 6.60 | 3.07 | 0.4176 | 1.69 | 4.29 | 354,283.20 | 6.27 | 6.21 | 9.78 | 10.38 | 67.85 | 68.84 | 15.02 | 12.69 | 0.5358 | 10.26 | 0.5407 | 113.09 | 1.02 | 7.35 | 23.77 | -7.35 | 3.33 | 0.00 |
| Sanofi SA | 32.65bn | 5.24bn | 91.74bn | 99.41k | 17.40 | -- | 13.94 | 2.81 | 4.92 | 4.92 | 30.71 | -- | -- | -- | -- | 387,237.00 | -- | 4.98 | -- | 5.97 | 68.26 | 68.13 | 16.12 | 14.73 | -- | 29.35 | -- | 69.80 | -0.6962 | 1.40 | 323.60 | 22.79 | -5.28 | 1.78 |
| AstraZeneca plc | 24.65bn | 1.11bn | 129.62bn | 76.10k | 87.89 | 4.34 | 26.40 | 5.26 | 0.952 | 0.952 | 18.11 | 19.27 | 0.3831 | 1.33 | 4.71 | 323,959.90 | 1.71 | 3.88 | 2.31 | 5.46 | 71.20 | 80.97 | 4.47 | 10.19 | 0.6835 | 2.41 | 0.4443 | 141.03 | 9.16 | 1.50 | 139.40 | 2.50 | -1.34 | 0.2156 |
| Novo Nordisk A/S | 15.35bn | 5.27bn | 144.67bn | 46.98k | 35.80 | 24.60 | 24.63 | 9.42 | 19.99 | 19.99 | 58.24 | 29.10 | 0.8573 | 1.25 | 4.97 | 3,009,749.00 | 29.41 | 35.30 | 59.69 | 67.18 | 82.89 | 84.10 | 34.31 | 33.51 | 0.8187 | -- | 0.1722 | 50.32 | 4.04 | 3.30 | 8.18 | 3.87 | 28.08 | 7.29 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 01 Nov 2021 | 152.00m | 3.02% |
| BlackRock Fund Advisorsas of 03 Mar 2021 | 131.21m | 2.61% |
| Norges Bank Investment Managementas of 01 Nov 2021 | 117.65m | 2.34% |
| Dodge & Coxas of 03 Mar 2021 | 99.38m | 1.98% |
| Capital Research & Management Co. (Global Investors)as of 01 Nov 2021 | 75.94m | 1.51% |
| BlackRock Advisors (UK) Ltd.as of 01 Nov 2021 | 68.79m | 1.37% |
| State Street Global Advisors Ltd.as of 01 Nov 2021 | 65.87m | 1.31% |
| Schroder Investment Management Ltd.as of 01 Nov 2021 | 65.05m | 1.29% |
| Threadneedle Asset Management Ltd.as of 01 Nov 2021 | 58.78m | 1.17% |
| Silchester International Investors LLPas of 01 Nov 2021 | 56.97m | 1.13% |
